FIBROSING INTERSTITIAL LUNG DISEASE

Clinical trials for FIBROSING INTERSTITIAL LUNG DISEASE explained in plain language.

Never miss a new study

Get alerted when new FIBROSING INTERSTITIAL LUNG DISEASE trials appear

Sign up with your email to follow new studies for FIBROSING INTERSTITIAL LUNG DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New hope for kids with scarring lung disease

Disease control Not yet recruiting

This study is testing an oral medication called nerandomilast in children and adolescents aged 2 to 17 who have fibrosing interstitial lung disease, a condition that causes scarring in the lungs. The main goals are to see how the body processes the drug, check its safety, and gat…

Matched conditions: FIBROSING INTERSTITIAL LUNG DISEASE

Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control

Last updated Apr 02, 2026 03:56 UTC

FIBROSING INTERSTITIAL LUNG DISEASE

Get alerted when new FIBROSING INTERSTITIAL LUNG DISEASE trials appear

New hope for kids with scarring lung disease